x

Coronavirus

Oregon Hospitals Will Be Provided with an Experimental COVID-19 Drug

PORTLAND, Ore. — Oregon health officials say hospitals will be provided with an experimental drug that has shown some promise treating the coronavirus.

The Oregon Health Authority said Sunday that the state has received enough doses of remdesivir to treat all patients who met the medical criteria for using the drug as of Saturday.

Recent early results for the drug suggested it could help patients recover from the coronavirus faster, although longer-term data is still needed to confirm any benefit.

The health authority is not taking a position on whether it should be used or not, leaving that decision up to doctors and their patients.

RELATED

LONDON (AP) — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

This article is part of a continuing series dealing with reports of Greek POWs in Asia Minor in the Thessaloniki newspaper, Makedonia in July 1936.

To the Editor: I am contacting you because of your relationship with Prime Minister Kyriakos Mitsotakis.

The words Chicago and Greek go together, especially when it comes to food, so the Chicago Greek restaurant has drawn a lot of customers to its Mesquite, NV location but it was sold by former owners Tassos Spentzos and Laura Andrews.

The Philadelphia Inquirer’s food critic Craig LaBan was a fan of humble patty melts, mushroom barley soup, and stuffed cabbage at Little Pete’s Greek eatery that brought comfort food, but not of what replaced it: the upscale Almyra restaurant.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.